News Releases

ATLANTA , May 16, 2022 /PRNewswire/ --   Artivion, Inc. (NYSE: AORT) , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in the upcoming UBS 2022 Global Healthcare Conference on Monday, May 23, 2022 at the Lotte New York Palace .

Achieved revenue of $77.2 million in the first quarter 2022 versus $71.1 million in the first quarter of 2021, an increase of 8.6% on a GAAP basis and 11.2% on a non-GAAP constant currency basis ATLANTA , May 5, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular

ATLANTA , April 21, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2022 financial results will be released on Thursday, May 5, 2022 after the market closes.

ATLANTA , March 31, 2022 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming 21 st Annual Needham Virtual Healthcare Conference .

ATLANTA , March 14, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today published its inaugural Corporate Responsibility Report detailing the company's Environmental, Social, and Governance (ESG) initiatives.

ATLANTA , March 9, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will host an Investor & Analyst Day in New York City on Wednesday, March 23, 2022 at 9:00 AM ET .

ATLANTA , March 3, 2022 /PRNewswire/ --  Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 32 nd Annual Healthcare Conference.

ATLANTA , Feb. 17, 2022 /PRNewswire/ --     Fourth Quarter and Recent Business Highlights: Achieved record revenue of $79.4 million in the fourth quarter 2021 versus $67.9 million in the fourth quarter of 2020, an increase of 16.9% on a GAAP basis and 18.8 % on a non-GAAP proforma constant currency

ATLANTA , Feb. 3, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the market closes.  On that

Results Presented at the 2022 Annual Meeting for The Society of Thoracic Surgeons ATLANTA, Jan. 31, 2022 /PRNewswire/ -- Artivion, Inc. (NYSE:  AORT ), a leading cardiac and vascular surgery company focused on aortic disease, today announced the publication of PROACT clinical trial results in  The